CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
3.750
-0.130 (-3.35%)
May 13, 2026, 1:02 PM EDT - Market open

CytomX Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
35.5476.2138.1101.2153.1637.31
Revenue Growth (YoY)
-75.91%-44.82%36.45%90.38%42.48%-45.47%
Gross Profit
35.5476.2138.1101.2153.1637.31
Selling, General & Admin
31.129.8429.7330.0242.8539.16
Research & Development
69.168.7383.3877.68111.65114.19
Total Operating Expenses
100.298.57113.11107.7154.5153.35
Operating Income
-64.66-22.3625-6.48-101.34-116.04
Interest Income
5.745.217.149.841.680.26
Other Non-Operating Income (Expense)
0.010.03-0.04-0.030.34-0.08
Total Non-Operating Income (Expense)
5.755.237.19.812.020.17
Pretax Income
-58.91-17.1332.093.32-99.32-115.87
Provision for Income Taxes
0.230.240.223.89--
Net Income
-59.14-20.3731.87-0.57-99.32-115.87
Net Income Attributable to Preferred Dividends
-3----
Net Income to Common
-59.14-20.3731.87-0.57-99.32-115.87
Shares Outstanding (Basic)
16013884746664
Shares Outstanding (Diluted)
15913885746664
Shares Change (YoY)
85.61%62.77%14.82%12.27%2.48%39.01%
EPS (Basic)
-0.41-0.150.38-0.01-1.51-1.81
EPS (Diluted)
-0.41-0.150.38-0.01-1.51-1.81
Shares Outstanding
177.27170.1980.173.8166.2365.25
Free Cash Flow
-80.19-75.81-86.54-56.88-112.53-120.64
Free Cash Flow Per Share
-0.50-0.55-1.02-0.77-1.71-1.88
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-181.92%-29.35%18.10%-6.41%-190.61%-311.00%
Profit Margin
-166.40%-22.79%23.08%-0.56%-186.82%-310.54%
FCF Margin
-225.63%-99.48%-62.66%-56.19%-211.67%-323.33%
EBITDA
-63.42-20.9926.76-4.31-98.89-113.34
EBITDA Margin
-178.43%-27.54%19.38%-4.26%-186.02%-303.75%
EBIT
-64.66-22.3625-6.48-101.34-116.04
EBIT Margin
-181.92%-29.35%18.10%-6.41%-190.61%-311.00%
Effective Tax Rate
-0.40%-1.39%0.70%117.12%0.00%0.00%
Updated May 7, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q